2 completed, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Transarterial Chemoembolization: new trials by email Literature Review of Transarterial Chemoembolization trials Research Report on Transarterial Chemoembolization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma DEB-TACE combined with apatinib and PD-1 antibody - Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 20 | 2024-07-01 | 2026-04-07 |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC cTACE-HAIC - Transarterial Chemoembolization, Hepatocellular Carcinoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 66 | 2020-10-20 | 2020-10-22 |
| The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma lenvatinib + sindilimab/carrelizumab, TACE - Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization | Phase 1 / Phase 2 | Completed | Xinrui Zhu，MD | 142 | 2020-10-01 | 2025-08-29 |
Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1)
Adenocarcinoma (2) · Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms by Site (1)
apatinib (1) · camrelizumab (1) · lenvatinib (1)
Peking University Cancer Hospital & Institute (1) · Sichuan Cancer Hospital and Research Institute (1) · Xinrui Zhu，MD (1)
China (2)
Xu Zhu (1)